1 Dividend Stock to Rule Them All
Mirror, mirror, on the wall, what's the greatest dividend stock of them all?
How Johnson & Johnson Spent $71 Billion in 12 Months
A slideshow reveals three interesting points about the pharmaceutical giant.
Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Johnson & Johnson's newly approved multiple myeloma drug, Darzalex, is worth keeping an eye on for a number of reasons.